DOCSLIB.ORG

N6-Methyladenosine Modification Destabilizes Developmental

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

LETTERS N 6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells Yang Wang1, Yue Li2, Julia I. Toth1, Matthew D. Petroski1, Zhaolei Zhang2,3 and Jing Crystal Zhao1,4 N6-methyladenosine (m6A) has been identified as the most An NCBI Blast Protein sequence analysis revealed greater than 35% abundant internal modification of messenger RNA in sequence homology of the MTase domain between Mettl3 and Mettl14 eukaryotes1. m6A modification is involved in cell fate (Fig. 1a), suggesting that both are MTases. To investigate this possibility determination in yeast2,3 and embryo development in plants4,5. we constructed short hairpin RNAs (shRNAs) targeting Mettl3 or Its mammalian function remains unknown but thousands of Mettl14 and generated mESC lines harbouring efficient KD of each mammalian mRNAs and long non-coding RNAs (lncRNAs) (Fig. 1b). We then used two independent methods to determine m6A show m6A modification6,7 and m6A demethylases are required levels in KD mESCs. First, immunoblotting of RNA samples using a for mammalian energy homeostasis and fertility8,9. We identify highly specific α-m6A antibody6,7 indicated decreased m6A levels in two proteins, the putative m6A MTase, methyltransferase-like 3 both Mettl3 KD and Mettl14 KD versus control cells (Fig. 1c). We then (Mettl3; ref. 10), and a related but uncharacterized protein used liquid chromatography–tandem mass spectrometry to quantify Mettl14, that function synergistically to control m6A formation m6A=A ratios and observed a 60–70% decrease in m6A levels in each KD in mammalian cells. Knockdown of Mettl3 and Mettl14 in line relative to controls (Fig. 1d), suggesting that both proteins mediate mouse embryonic stem cells (mESCs) led to similar m6A formation in vivo. mESCs expressing additional shRNAs targeting phenotypes, characterized by lack of m6A RNA methylation and Mettl3 or Mettl14 were generated to control for shRNA off-target lost self-renewal capability. A large number of transcripts, effects (Supplementary Fig. 1A) and similarly decreased m6A levels were including many encoding developmental regulators, exhibit detected in all KD clones (Supplementary Fig. 1B). We then carried out m6A methylation inversely correlated with mRNA stability and a direct methylation assay by incubating an RNA probe exhibiting four gene expression. The human antigen R (HuR) and microRNA repeats of the canonical m6A methylation motif (GGACU) with equal pathways were linked to these effects. This gene regulatory amounts of luciferase, Mettl3 and/or Mettl14 proteins (Fig. 1e and mechanism operating in mESCs through m6A methylation is Supplementary Fig. 1C) purified from HEK293 cells in the presence required to keep mESCs at their ground state and may be of [3H]SAM and assessed [3H]methyl transfer. The RNA probe relevant to thousands of mRNAs and lncRNAs in various cell incubated with control luciferase protein showed no increase in [3H] types. levels. However, 1.5-, 3.5- and >27-fold increases in [3H] levels were detected in probes incubated with Mettl3, Mettl14 and Mettl3CMettl14 RNA and DNA MTases share structural motifs required to transfer (Fig. 1f), respectively. Thin-layer chromatography analysis confirmed methyl groups from S-adenosyl-l-methionine (SAM) to nucleic that methylated nucleotides were m6A(Fig. 1g and Supplementary acid. Previously, two mammalian m6A MTases, Mettl3 and Mettl14, Fig. 1D). To exclude the possibility that the enzymatic activity was were predicted computationally on the basis of conservation of the due to promiscuously co-purified mammalian proteins, we performed SAM-binding domain and phylogenetic analysis11,12. Mettl3 purified methylation assays using proteins purified from baculovirus-infected from HeLa cell nuclear extracts functions as a putative MTase (ref. 10). Sf9 insect cells. We found Mettl3 and Mettl14 difficult to purify Mettl14 remains uncharacterized. A recent study reported altered RNA alone but they were easily co-purified when co-expressed. As shown splicing in Mettl3 knockdown (KD) HeLa cells7, but as yet no direct in Supplementary Fig. 1E, Mettl3 was specifically pulled down by evidence links Mettl3 to m6A formation. Mettl14 but not luciferase, suggesting a strong interaction between 1Tumor Initiation and Maintenance Program, NCI-designated Cancer Center, Sanford Burnham Medical Research Institute, La Jolla, California 92037, USA. 2Department of Computer Science, The Donnelly Centre, University of Toronto, Toronto M5S 3G4, Canada. 3Department of Molecular Genetics, Donnelly Centre for Cellular and Biomolecular Research, Banting and Best Department of Medical Research, University of Toronto, Toronto M5S 3G4, Canada. 4Correspondence should be addressed to J.C.Z. (e-mail: [email protected]) Received 24 May 2013; accepted 29 November 2013; published online 7 January 2014; DOI: 10.1038/ncb2902 NATURE CELL BIOLOGY ADVANCE ONLINE PUBLICATION 1 © 2014 Macmillan Publishers Limited. All rights reserved. LETTERS a SAM-binding domain Mettl3 1 580 Mettl14 1 456 Mettl3 AVVMADPPWD I HME LPYGT L TDDEMRRLN I PVLQDD–GF L FLWVT– GRAME LGRECLNLW 5 8 Mettl14 – – – – – – – – – ETG I TANEKCWTWDD I MKLE I DE I AAPRSF I FLWCGSGEGLDLGRVCLRKW 5 1 Mettl3 GYERVDE I I WVKTNQLQR – I I RTGRTGHWLNHGKEHCL VGVKGNPQGFNQG– – – – – –LDC 1 11 Mettl14 GYRRCED I CW I KTNKNNPGKT KTLDPKAVFQRTKEHCLMG I KG TVKRSTDGDF I HANVD I 1 11 Mettl3 DV I VAEVRS TS– –HKPDE I YGM I ERLSPGTRK I EL FGRPHNVQPNW I T LGNQ 1 6 1 Mettl14 D L I I TEEPE I GN I EKPVE I FH I I EHFCLGRRRLHL FGRDST I R PGWLTVGPT 1 6 3 b c Mettl3 Mettl14 M Scr shM3 shM14 Scr shM3 shM14 1.0 1.0 bp 6,583 Scr shM3 4,981 Mettl3 Scr shM14 3,638 0.5 Mettl14 Gapdh 0.5 2,604 Gapdh ∗∗∗ 1,908 Relative expression 1,383 Relative mRNA levels ∗∗∗∗ 955 0 0 623 shM3 shM14 281 Scramble Scramble d 0.20 e Replicate 1 LucM3 M14 M3 + M14 0.15 Replicate 2 Anti-flag 0.10 Anti-Mettl3 A/A (%) 6 m Anti-Mettl14 0.05 0 Scr shM3 shM14 fg∗∗∗∗ ∗∗∗∗ 400 1,000 ∗∗∗∗ A 300 6 ) ∗∗ m A 10 100 c.p.m. 200 10 c.p.m. (log 100 ∗∗∗ ∗ 1 0 Luc M3 Luc M3 Mock M14 M14 M3 + M14 M3 + M14 Figure 1 Mettl3 and Mettl14 are required for m6A formation in vitro and KD, Mettl14 KD and control cells. (d) Measurement of percentage of m6A=A in vivo.(a) Schematic drawing showing predicted MTase domains of mouse ratio by MS. (e) Flag, Mettl3 or Mettl14 western immunoblots of proteins Mettl3 (Accession: NP_062695:2) and Mettl14 (Accession: NP_964000:2) purified from lysates of HEK293 cells overexpressing flag-tagged Mettl3, proteins. Numbers represent amino acid numbers. (b) RT–qPCR (left) and Mettl14, or luciferase using M2 beads. Luc, luciferase; M3, Mettl3; M14, western blot (right) showing Mettl3 (left panel) and Mettl14 (right panel) Mettl14. The original gel is shown in Supplementary Fig. 5. (f) c.p.m. of RNA expression in mESC clones stably expressing shRNAs targeting each. Gapdh probes extracted after an in vitro methylation assay. (g) c.p.m. of excised m6A serves as a loading control in the western blot. Scr: scramble; shM3, shRNA spots from digested RNA probes used in the methylation assay. Error bars against Mettl3; shM14, shRNA against Mettl14. The original gel is shown in in b,f,g represent means ± s.e.m. from three separate experiments, except Supplementary Fig. 5. (c) Ethidium bromide staining (left panel) and m6A M3 in g where n D 7. One-tailed Student's t -test, ∗P < 0:05, ∗∗P < 0:01, immunoblot (right panel) of DNA-free, rRNA-free Poly(A)C RNA from Mettl3 ∗∗∗P <0:001, ∗∗∗∗P <0:0001 versus scramble control. Scr: scramble control. 2 NATURE CELL BIOLOGY ADVANCE ONLINE PUBLICATION © 2014 Macmillan Publishers Limited. All rights reserved. LETTERS a Sox17 Scr shM14 shM3 b Mettl3 KD Mettl14 KD cdMettl3 IP Mettl14 IP Scr shM14 shM3 1% 1% Anti-Mettl14 input M3-IP IgG input M14-IP IgG Anti-Mettl3 371 4,395 354 Anti-Mettl3 Anti-Mettl14 Anti-Gapdh ef 754 P × –50 Scr Regulation of transcription < 1.91 10 1.5 shM3 Alternative splicing 1,386 P < 2.82 × 10–48 shM14 Chromatin modification 94 P < 1.56 × 10–7 1.0 ∗ Programmed cell death 145 P < 1.37 × 10–3 Cell morphogenesis 102 P < 2.00 × 10–3 0.5 In utero 90 P < 3.46 × 10–3 ∗∗ embryonic development ∗∗∗ Neuronal differentiation 122 P < 1.30 × 10–2 Relative RNA levels P × –2 0 Blood vessel development 81 < 2.25 10 P × –2 Heart development 75 < 2.96 10 Mettl3 Mettl14 0204060 P Hypergeometric enrichment (–log10( value)) Figure 2 Mettl3 and Mettl14 interact and regulate each other's stability. in Supplementary Fig. 5. (d) Western blot analysis of Mettl3 and Mettl14 (a) meRIP-seq analysis of a Sox17 transcript showing loss of m6A protein levels in Mettl3 KD and Mettl14 KD mESCs, respectively. The methylation in both Mettl3 KD and Mettl14 KD cells. Yellow highlighting, original gel is shown in Supplementary Fig. 5. (e) RT–qPCR analysis of peak location. Scr: scramble; shM3, shRNA against Mettl3; shM14, shRNA Mettl3 and Mettl14 RNA levels in Mettl3 KD and Mettl14 KD mESCs, against Mettl14.(b) Venn diagram showing overlap of Mettl3 and Mettl14 respectively. (f) GO analysis of 4,395 shared Mettl3 and Mettl14 targets. targets. (c) Mettl3 or Mettl14 western immunoblots of endogenous proteins Error bars in e represent means ± s.e.m. from three separate experiments. co-immunoprecipitated using antibodies against Mettl3 or Mettl14, or IgG One-tailed Student's t -test, ∗P < 0:05, ∗∗P < 0:01, ∗∗∗P < 0:001 versus in mESC lysates. M3, Mettl3; M14, Mettl14. The original gel is shown scramble control. Scr: scramble. Mettl3 and Mettl14. Importantly, Mettl3 C Mettl14 exhibited high 4,766 genes in Mettl3 KD and 4,749 in Mettl14 KD cells showed m6A MTase activity (Supplementary Fig. 1F,G), demonstrating that significantly decreased transcript m6A levels relative to controls.
Recommended publications
  • METTL3-Mediated M6a Modification Is Required for Cerebellar Development

    METTL3-Mediated M6a Modification Is Required for Cerebellar Development

    RESEARCH ARTICLE METTL3-mediated m6A modification is required for cerebellar development Chen-Xin Wang1,2☯, Guan-Shen Cui3,4☯, Xiuying Liu5☯, Kai Xu1,2☯, Meng Wang5☯, Xin- Xin Zhang1, Li-Yuan Jiang1, Ang Li2,3, Ying Yang3, Wei-Yi Lai2,6, Bao-Fa Sun2,3,7, Gui- Bin Jiang6, Hai-Lin Wang6, Wei-Min Tong8, Wei Li1,2,7, Xiu-Jie Wang2,5,7*, Yun- Gui Yang2,3,7*, Qi Zhou1,2,7* 1 State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China, 2 University of Chinese Academy of Sciences, Beijing, China, 3 Key Laboratory of Genomic and Precision Medicine, Collaborative Innovation Center of Genetics and Development, Beijing a1111111111 Institute of Genomics, Chinese Academy of Sciences, Beijing, China, 4 Sino-Danish College, University of a1111111111 Chinese Academy of Sciences, Beijing, China, 5 Key Laboratory of Genetic Network Biology, Institute of a1111111111 Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, China, 6 State Key Laboratory a1111111111 of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese a1111111111 Academy of Sciences, Beijing, China, 7 Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China, 8 Department of Pathology, Center for Experimental Animal Research, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China ☯ These authors contributed equally to this work. OPEN ACCESS * [email protected] (XJW); [email protected] (YGY); [email protected] (QZ) Citation: Wang C-X, Cui G-S, Liu X, Xu K, Wang M, Zhang X-X, et al.
  • 'Next- Generation' Sequencing Data Analysis

    'Next- Generation' Sequencing Data Analysis

    Novel Algorithm Development for ‘Next- Generation’ Sequencing Data Analysis Agne Antanaviciute Submitted in accordance with the requirements for the degree of Doctor of Philosophy University of Leeds School of Medicine Leeds Institute of Biomedical and Clinical Sciences 12/2017 ii The candidate confirms that the work submitted is her own, except where work which has formed part of jointly-authored publications has been included. The contribution of the candidate and the other authors to this work has been explicitly given within the thesis where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement ©2017 The University of Leeds and Agne Antanaviciute The right of Agne Antanaviciute to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. Acknowledgements I would like to thank all the people who have contributed to this work. First and foremost, my supervisors Dr Ian Carr, Professor David Bonthron and Dr Christopher Watson, who have provided guidance, support and motivation. I could not have asked for a better supervisory team. I would also like to thank my collaborators Dr Belinda Baquero and Professor Adrian Whitehouse for opening new, interesting research avenues. A special thanks to Dr Belinda Baquero for all the hard wet lab work without which at least half of this thesis would not exist. Thanks to everyone at the NGS Facility – Carolina Lascelles, Catherine Daley, Sally Harrison, Ummey Hany and Laura Crinnion – for the generation of NGS data used in this work and creating a supportive and stimulating work environment.
  • Large-Scale Functional Prediction of Individual M6a RNA Methylation Sites from an RNA Co-Methylation Network

    Large-Scale Functional Prediction of Individual M6a RNA Methylation Sites from an RNA Co-Methylation Network

    Wu et al. BMC Bioinformatics (2019) 20:223 https://doi.org/10.1186/s12859-019-2840-3 RESEARCHARTICLE Open Access m6Acomet: large-scale functional prediction of individual m6A RNA methylation sites from an RNA co- methylation network Xiangyu Wu1,2, Zhen Wei1,2, Kunqi Chen1,2, Qing Zhang1,4, Jionglong Su5, Hui Liu6, Lin Zhang6* and Jia Meng1,3* Abstract Background: Over one hundred different types of post-transcriptional RNA modifications have been identified in human. Researchers discovered that RNA modifications can regulate various biological processes, and RNA methylation, especially N6-methyladenosine, has become one of the most researched topics in epigenetics. Results: To date, the study of epitranscriptome layer gene regulation is mostly focused on the function of mediator proteins of RNA methylation, i.e., the readers, writers and erasers. There is limited investigation of the functional relevance of individual m6A RNA methylation site. To address this, we annotated human m6A sites in large-scale based on the guilt-by-association principle from an RNA co-methylation network. It is constructed based on public human MeRIP-Seq datasets profiling the m6A epitranscriptome under 32 independent experimental conditions. By systematically examining the network characteristics obtained from the RNA methylation profiles, a total of 339,158 putative gene ontology functions associated with 1446 human m6A sites were identified. These are biological functions that may be regulated at epitranscriptome layer via reversible m6A RNA methylation. The results were further validated on a soft benchmark by comparing to a random predictor. Conclusions: An online web server m6Acomet was constructed to support direct query for the predicted biological functions of m6A sites as well as the sites exhibiting co-methylated patterns at the epitranscriptome layer.
  • Promoter-Bound METTL3 Maintains Myeloid Leukaemia Via M6a-Dependent Translation Control

    Promoter-Bound METTL3 Maintains Myeloid Leukaemia Via M6a-Dependent Translation Control

    1 2 Promoter-bound METTL3 maintains myeloid leukaemia 3 via m6A-dependent translation control 4 5 6 Isaia Barbieri1*, Konstantinos Tzelepis2*, Luca Pandolfini1*, Junwei Shi3♯, Gonzalo Millán- 7 Zambrano1, Samuel C. Robson1¶, Demetrios Aspris2, Valentina Migliori1, Andrew J. 8 Bannister1, Namshik Han1, Etienne De Braekeleer2, Hannes Ponstingl2, Alan Hendrick4, 9 Christopher R. Vakoc3, George S. Vassiliou2§ & Tony Kouzarides1§. 10 11 1The Gurdon Institute and Department of Pathology, University of Cambridge, Tennis Court Road, 12 Cambridge, CB2 1QN, UK. 13 2 Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, CB10 1SA, UK. 14 3 Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA. 15 4 Storm Therapeutics Ltd, Moneta building (B280), Babraham Research Campus, Cambridge CB22 3AT, UK. 16 17 ♯ Present address: Department of Cancer Biology, Abramson Family Cancer Research Institute, Perelman 18 School of Medicine, University of Pennsylvania, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104, 19 USA. 20 ¶Present address: School of Pharmacy & Biomedical Science, St Michael's Building, University of 21 Portsmouth, White Swan Road, Portsmouth, UK" 22 *These authors contributed equally to the work. 23 §Corresponding authors ([email protected]; [email protected]) 24 25 26 27 Abstract 28 29 N6-methyladenosine (m6A) is an abundant internal RNA modification in both coding1 and 30 non-coding RNAs2,3, catalysed by the METTL3/METTL14 methyltransferase complex4. 31 Here we define a novel pathway specific for METTL3, implicated in the maintenance of the 32 leukaemic state. We identify METTL3 as an essential gene for growth of acute myeloid 33 leukaemia (AML) cells in two distinct genetic screens.
  • B01P) Gene Alias: IME4, M6A, MGC4336, MT-A70, Spo8

    B01P) Gene Alias: IME4, M6A, MGC4336, MT-A70, Spo8

    METTL3 purified MaxPab mouse Gene Symbol: METTL3 polyclonal antibody (B01P) Gene Alias: IME4, M6A, MGC4336, MT-A70, Spo8 Catalog Number: H00056339-B01P Gene Summary: This gene encodes the 70 kDa subunit of MT-A which is part of Regulatory Status: For research use only (RUO) N6-adenosine-methyltransferase. This enzyme is involved in the posttranscriptional methylation of internal Product Description: Mouse polyclonal antibody raised adenosine residues in eukaryotic mRNAs, forming against a full-length human METTL3 protein. N6-methyladenosine. [provided by RefSeq] Immunogen: METTL3 (NP_062826.2, 1 a.a. ~ 580 a.a) References: full-length human protein. 1. Synaptic N6-methyladenosine (m6A) epitranscriptome Sequence: reveals functional partitioning of localized transcripts. MSDTWSSIQAHKKQLDSLRERLQRRRKQDSGHLDLR Merkurjev D, Hong WT, Iida K, Oomoto I, Goldie BJ, NPEAALSPTFRSDSPVPTAPTSGGPKPSTASAVPELAT Yamaguti H, Ohara T, Kawaguchi SY, Hirano T, Martin DPELEKKLLHHLSDLALTLPTDAVSICLAISTPDAPATQ KC, Pellegrini M, Wang DO. Nat Neurosci. 2018 DGVESLLQKFAAQELIEVKRGLLQDDAHPTLVTYADHS Jul;21(7):1004-1014. doi: 10.1038/s41593-018-0173-6. KLSAMMGAVAEKKGPGEVAGTVTGQKRRAEQDSTTV Epub 2018 Jun 27. AAFASSLVSGLNSSASEPAKEPAKKSRKHAASDVDLEI 2. The RNA Methyltransferase Complex of WTAP, ESLLNQQSTKEQQSKKVSQEILELLNTTTAKEQSIVEKF METTL3, and METTL14 Regulates Mitotic Clonal RSRGRAQVQEFCDYGTKEECMKASDADRPCRKLHFR Expansion in Adipogenesis. Kobayashi M, Ohsugi M, RIINKHTDESLGDCSFLNTCFHMDTCKYVHYEIDACMD Sasako T, Awazawa M, Umehara T, Iwane A, Kobayashi SEAPGSKDHTPSQELALTQSVGGDSSADRLFPPQWIC
  • N6-Methyladenosine RNA Modification Regulates Embryonic Neural Stem Cell Self-Renewal Through Histone Modifications

    N6-Methyladenosine RNA Modification Regulates Embryonic Neural Stem Cell Self-Renewal Through Histone Modifications

    ARTICLES https://doi.org/10.1038/s41593-017-0057-1 Corrected: Publisher Correction N6-methyladenosine RNA modification regulates embryonic neural stem cell self-renewal through histone modifications Yang Wang1, Yue Li 2, Minghui Yue3,4, Jun Wang1, Sandeep Kumar5, Robert J. Wechsler-Reya1, Zhaolei Zhang6, Yuya Ogawa3,4, Manolis Kellis2, Gregg Duester 5 and Jing Crystal Zhao 1* Internal N6-methyladenosine (m6A) modification is widespread in messenger RNAs (mRNAs) and is catalyzed by heterodimers of methyltransferase-like protein 3 (Mettl3) and Mettl14. To understand the role of m6A in development, we deleted Mettl14 in embryonic neural stem cells (NSCs) in a mouse model. Phenotypically, NSCs lacking Mettl14 displayed markedly decreased proliferation and premature differentiation, suggesting that m6A modification enhances NSC self-renewal. Decreases in the NSC pool led to a decreased number of late-born neurons during cortical neurogenesis. Mechanistically, we discovered a genome-wide increase in specific histone modifications in Mettl14 knockout versus control NSCs. These changes correlated with altered gene expression and observed cellular phenotypes, suggesting functional significance of altered histone modi- fications in knockout cells. Finally, we found that m6A regulates histone modification in part by destabilizing transcripts that encode histone-modifying enzymes. Our results suggest an essential role for m6A in development and reveal m6A-regulated histone modifications as a previously unknown mechanism of gene regulation in mammalian cells. ost-transcriptional modification of mRNA has emerged as an (VZ) showed a decrease in number relative to those seen in control important mechanism for gene regulation. Among internal mice, and this reduction was accompanied by fewer late-born corti- mRNA modifications, m6A is by far the most abundant, tagging cal neurons.
  • RNA–Protein Interaction Mapping Via MS2- Or Cas13-Based APEX Targeting

    RNA–Protein Interaction Mapping Via MS2- Or Cas13-Based APEX Targeting

    RNA–protein interaction mapping via MS2- or Cas13-based APEX targeting Shuo Hana,b,c,1, Boxuan Simen Zhaoa,b,c,1, Samuel A. Myersd, Steven A. Carrd, Chuan Hee,f, and Alice Y. Tinga,b,c,2 aDepartment of Genetics, Chan Zuckerberg Biohub, Stanford University, Stanford, CA 94305; bDepartment of Biology, Chan Zuckerberg Biohub, Stanford University, Stanford, CA 94305; cDepartment of Chemistry, Chan Zuckerberg Biohub, Stanford University, Stanford, CA 94305; dThe Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142; eDepartment of Chemistry, Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago, Chicago, IL 60637; and fDepartment of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago, Chicago, IL 60637 Edited by Robert H. Singer, Albert Einstein College of Medicine, Bronx, NY, and approved July 24, 2020 (received for review April 8, 2020) RNA–protein interactions underlie a wide range of cellular pro- and oncogenesis by serving as the template for reverse transcrip- cesses. Improved methods are needed to systematically map RNA– tion of telomeres (26, 27). While hTR’s interaction with the protein interactions in living cells in an unbiased manner. We used telomerase complex has been extensively characterized (28), hTR two approaches to target the engineered peroxidase APEX2 to is present in stoichiometric excess over telomerase in cancer cells specific cellular RNAs for RNA-centered proximity biotinylation of (29) and is broadly expressed in tissues lacking telomerase protein protein interaction partners. Both an MS2-MCP system and an (30). These observations suggest that hTR could also function engineered CRISPR-Cas13 system were used to deliver APEX2 to outside of the telomerase complex (31), and uncharacterized the human telomerase RNA hTR with high specificity.
  • Novel Insights Into the M6a-RNA Methyltransferase METTL3 in Cancer

    Novel Insights Into the M6a-RNA Methyltransferase METTL3 in Cancer

    Cai et al. Biomarker Research (2021) 9:27 https://doi.org/10.1186/s40364-021-00278-9 REVIEW Open Access Novel insights into the m6A-RNA methyltransferase METTL3 in cancer Yiqing Cai1†, Rui Feng2†, Tiange Lu1, Xiaomin Chen1, Xiangxiang Zhou1,2,3,4,5,6* and Xin Wang1,2,3,4,5,6* Abstract N6-methyladenosine (m6A) is a prevalent internal RNA modification in higher eukaryotic cells. As the pivotal m6A regulator, RNA methyltransferase-like 3 (METTL3) is responsible for methyl group transfer in the progression of m6A modification. This epigenetic regulation contributes to the structure and functional regulation of RNA and further promotes tumorigenesis and tumor progression. Accumulating evidence has illustrated the pivotal roles of METTL3 in a variety of human cancers. Here, we systemically summarize the interaction between METTL3 and RNAs, and illustrate the multiple functions of METTL3 in human cancer. METLL3 is aberrantly expressed in a variety of tumors. Elevation of METTL3 is usually associated with rapid progression and poor prognosis of tumors. On the other hand, METTL3 may also function as a tumor suppressor in several cancers. Based on the tumor-promoting effect of METT L3, the possibility of applying METTL3 inhibitors is further discussed, which is expected to provide novel insights into antitumor therapy. Keywords: N6-methyladenosine, METTL3, RNA regulation, Tumorigenesis Introduction performed by “writers”, while the modification site is Epigenetics promotes the functional plasticity of genome subsequently “read” by m6A recognition proteins or at multiple levels [1]. As the classical kinds of chemical “erased” by m6A demethylases [12]. In particular, human modifications, 5-methylcytidine (m5C), 5- N6-methyltransferase complex (MTC), which contains hydroxymethylcytidine (hm5C), N4-acetylcytidine (ac4C), Methyltransferase-like 3 (METTL3) [13], METTL14 and N6-methyladenosine (m6A) mainly participate in [14], Wilms tumor 1-associated protein (WTAP) [15], the epigenetic modification of RNAs [2].
  • RNA M6 a Modification Enzymes Shape Innate Responses to DNA by Regulating Interferon Β

    RNA M6 a Modification Enzymes Shape Innate Responses to DNA by Regulating Interferon Β

    Downloaded from genesdev.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press RNA m6A modification enzymes shape innate responses to DNA by regulating interferon β Rosa M. Rubio,1 Daniel P. Depledge,1 Christopher Bianco,1 Letitia Thompson,1 and Ian Mohr1,2 1Department of Microbiology, 2Laura and Isaac Perlmutter Cancer Institute, New York University School of Medicine, New York, New York 10016, USA Modification of mRNA by N6-adenosine methylation (m6A) on internal bases influences gene expression in eukaryotes. How the dynamic genome-wide landscape of m6A-modified mRNAs impacts virus infection and host immune responses remains poorly understood. Here, we show that type I interferon (IFN) production triggered by dsDNA or human cytomegalovirus (HCMV) is controlled by the cellular m6A methyltrasferase subunit METTL14 and ALKBH5 demethylase. While METTL14 depletion reduced virus reproduction and stimulated dsDNA- or HCMV-induced IFNB1 mRNA accumulation, ALKBH5 depletion had the opposite effect. Depleting METTL14 increased both nascent IFNB1 mRNA production and stability in response to dsDNA. In contrast, ALKBH5 deple- tion reduced nascent IFNB1 mRNA production without detectably influencing IFN1B mRNA decay. Genome-wide transcriptome profiling following ALKBH5 depletion identified differentially expressed genes regulating antiviral immune responses, while METTL14 depletion altered pathways impacting metabolic reprogramming, stress responses, and aging. Finally, we determined that IFNB1 mRNA was m6A-modified within both the coding sequence and the 3′ untranslated region (UTR). This establishes that the host m6A modification machinery controls IFNβ production triggered by HCMV or dsDNA. Moreover, it demonstrates that responses to nonmicrobial dsDNA in uninfected cells, which shape host immunity and contribute to autoimmune disease, are regulated by enzymes controlling m6A epitranscriptomic changes.
  • 51104 METTL14 (D8K8W) Rabbit Mab

    51104 METTL14 (D8K8W) Rabbit Mab

    Revision 1 C 0 2 - t METTL14 (D8K8W) Rabbit mAb a e r o t S Orders: 877-616-CELL (2355) [email protected] Support: 877-678-TECH (8324) 4 0 1 Web: [email protected] 1 www.cellsignal.com 5 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source/Isotype: UniProt ID: Entrez-Gene Id: WB H M R Mk Endogenous 65 Rabbit IgG Q9HCE5 57721 Product Usage Information 5. Ping, X.L. et al. (2014) Cell Res 24, 177-89. 6. Lin, S. et al. (2016) Mol Cell 62, 335-45. Application Dilution 7. Jin, D.I. et al. (2012) Cancer Sci 103, 2102-9. 8. Jo, H.J. et al. (2013) J Gastroenterol 48, 1271-82. Western Blotting 1:1000 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody. Specificity / Sensitivity METTL14 (D8K8W) Rabbit mAb recognizes endogenous levels of total METL14 protein. Species Reactivity: Human, Mouse, Rat, Monkey Species predicted to react based on 100% sequence homology: Chicken, Xenopus Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro130 of human METTL14 protein. Background Methyltransferase-like protein 3 (METTL3) and methytransferase-like protein 14 (METTL14) are the two catalytic subunits of an N6-methyltransferase complex that methylates adenosine residues in RNA (1). Methylation of adenosine residues regulates mRNA splicing, processing, translation efficiency, editing and stability, in addition to regulating primary miRNA processing, and is critical for proper regulation of the circadian clock, embryonic stem cell self-renewal, immune tolerance, response to various stimuli, meiosis and mouse fertility (2,3).
  • Wide M6a Methylome in Preeclampsia and Healthy Control Placentas

    Wide M6a Methylome in Preeclampsia and Healthy Control Placentas

    Integrated analysis of the transcriptome- wide m6A methylome in preeclampsia and healthy control placentas Jin Wang1, Fengchun Gao2, Xiaohan Zhao1, Yan Cai1 and Hua Jin1 1 Prenatal Diagnosis Center, Jinan Maternal and Child Health Care Hospital, Jinan, China 2 Obstetrical Department, Jinan Maternal and Child Health Care Hospital, Jinan, China ABSTRACT N6-methyladenosine (m6A) is the most prevalent modification in eukaryotic mRNA and potential regulatory functions of m6A have been shown by mapping the RNA m6A modification landscape. m6A modification in active gene regulation manifests itself as altered methylation profiles. The number of reports regarding to the profiling of m6A modification and its potential role in the placenta of preeclampsia (PE) is small. In this work, placental samples were collected from PE and control patients. Expression of m6A-related genes was investigated using quantitative real-time PCR. MeRIP-seq and RNA-seq were performed to detect m6A methylation and mRNA expression profiles. Gene ontology (GO) functional and Kyoto encyclopedia of genes and genomes (KEGG) pathway analyses were also conducted to explore the modified genes and their clinical significance. Our findings show that METTL3 and METTL14 were up-regulated in PE. In total, 685 m6A peaks were differentially expressed as determined by MeRIP-seq. Altered peaks of m6A-modified transcripts were primarily associated with nitrogen compound metabolic process, positive regulation of vascular- associated smooth muscle cell migration, and endoplasmic reticulum organisation. The m6A hyper-methylated genes of Wnt/β-catenin signalling pathway, mTOR signalling pathway, and several cancer-related pathways may contribute to PE. We also verified that the significant increase of HSPA1A mRNA and protein expression was regulated by m6A modification, suggesting m6A plays a key role in the regulation of gene expression.
  • RNA M6a Methylation Participates in Regulation of Postnatal Development

    RNA M6a Methylation Participates in Regulation of Postnatal Development

    Ma et al. Genome Biology (2018) 19:68 https://doi.org/10.1186/s13059-018-1435-z RESEARCH Open Access RNA m6A methylation participates in regulation of postnatal development of the mouse cerebellum Chunhui Ma1†, Mengqi Chang1†, Hongyi Lv2,3†, Zhi-Wei Zhang1, Weilong Zhang4, Xue He1, Gaolang Wu1, Shunli Zhao1, Yao Zhang1, Di Wang1, Xufei Teng2,3, Chunying Liu1, Qing Li1, Arne Klungland5,6, Yamei Niu1* , Shuhui Song2* and Wei-Min Tong1* Abstract Background: N6-methyladenosine (m6A) is an important epitranscriptomic mark with high abundance in the brain. Recently, it has been found to be involved in the regulation of memory formation and mammalian cortical neurogenesis. However, while it is now established that m6A methylation occurs in a spatially restricted manner, its functions in specific brain regions still await elucidation. Results: We identify widespread and dynamic RNA m6A methylation in the developing mouse cerebellum and further uncover distinct features of continuous and temporal-specific m6A methylation across the four postnatal developmental processes. Temporal-specific m6A peaks from P7 to P60 exhibit remarkable changes in their distribution patterns along the mRNA transcripts. We also show spatiotemporal-specific expression of m6A writers METTL3, METTL14, and WTAP and erasers ALKBH5 and FTO in the mouse cerebellum. Ectopic expression of METTL3 mediated by lentivirus infection leads to disorganized structure of both Purkinje and glial cells. In addition, under hypobaric hypoxia exposure, Alkbh5-deletion causes abnormal cell proliferation and differentiation in the cerebellum through disturbing the balance of RNA m6A methylation in different cell fate determination genes. Notably, nuclear export of the hypermethylated RNAs is enhanced in the cerebellum of Alkbh5-deficient mice exposed to hypobaric hypoxia.